In this article, I’m going to take a look at Puma Biotechnology Inc’s (NASDAQ:PBYI) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...

The Los Angeles-based company said it had a loss of $2.07 per share. Losses, adjusted for stock option expense, were $1.36 per share. The results exceeded Wall Street expectations. The average estimate ...

Shares of Puma Biotechnology Inc. fell more than 8% late Thursday after the biotech company reported an adjusted third-quarter loss in line with expectations, and sales that were above Wall Street forecasts. ...

Puma Biotechnology Inc. said it has secured a term loan of up to $100 million to market its drug Nerlynx, which was recently approved by the U.S. Food and Drug Administration as a treatment to reduce the risk of breast cancer recurrence. Los Angeles-based Puma (PBYI) said it has entered into a loan agreement with Silicon Valley Bank and Oxford Finance , a specialty finance firm that provides senior debt to life sciences and health-care services companies.

A former Puma Biotechnology Inc executive pleaded guilty on Thursday to U.S. charges that he traded on inside information ahead of announcements by the biopharmaceutical company about a drug it was developing to treat breast cancer. Robert Gadimian, the Los Angeles-based company's former senior director of regulatory affairs, pleaded guilty in federal court in Boston to seven counts of securities fraud over illicit trades that prosecutors say allowed him to earn over $1 million. "Mr. Gadimian has fully accepted responsibility for his conduct," his lawyer, Christopher Bruno, said.

Biotech stocks have been a favorite of fast money, too, since it moves faster than the Standard & Poor’s 500 – in both directions. Some stocks, such as Vertex Pharmaceuticals (NASDAQ:VRTX), are already up triple-digit percentages this year. Or, they may be emerging from long trading ranges where uncertainty previously ruled.

On a per-share basis, the Los Angeles-based company said it had a loss of $2.10. Losses, adjusted for stock option expense, came to $1.38 per share. The results surpassed Wall Street expectations. The ...